Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) has been given a consensus rating of "Buy" by the seven ratings firms that are covering the company, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $43.50.
A number of equities research analysts have recently weighed in on the company. Scotiabank initiated coverage on Palvella Therapeutics in a research note on Friday, March 7th. They set a "sector outperform" rating and a $50.00 price target for the company. Canaccord Genuity Group reiterated a "buy" rating and issued a $39.00 target price on shares of Palvella Therapeutics in a research note on Wednesday, February 26th. HC Wainwright restated a "buy" rating and set a $38.00 price target on shares of Palvella Therapeutics in a research note on Tuesday, February 11th. Jones Trading started coverage on shares of Palvella Therapeutics in a report on Tuesday. They set a "buy" rating and a $45.00 price target on the stock. Finally, TD Cowen began coverage on shares of Palvella Therapeutics in a report on Wednesday, February 5th. They issued a "buy" rating and a $44.00 price objective for the company.
View Our Latest Stock Analysis on Palvella Therapeutics
Hedge Funds Weigh In On Palvella Therapeutics
A number of institutional investors have recently made changes to their positions in the business. Toronto Dominion Bank acquired a new stake in Palvella Therapeutics in the 4th quarter valued at approximately $159,000. Frazier Life Sciences Management L.P. acquired a new stake in shares of Palvella Therapeutics in the fourth quarter worth $7,847,000. Suvretta Capital Management LLC bought a new position in Palvella Therapeutics during the fourth quarter worth $8,574,000. DAFNA Capital Management LLC acquired a new position in Palvella Therapeutics during the 4th quarter valued at $857,000. Finally, Cresset Asset Management LLC acquired a new position in Palvella Therapeutics during the 4th quarter valued at $251,000. 40.11% of the stock is currently owned by institutional investors.
Palvella Therapeutics Stock Performance
PVLA traded up $0.34 during trading on Tuesday, reaching $28.10. 74,902 shares of the stock traded hands, compared to its average volume of 62,262. The firm's 50-day moving average price is $20.24. Palvella Therapeutics has a fifty-two week low of $6.20 and a fifty-two week high of $29.27. The stock has a market cap of $315.31 million, a PE ratio of -2.32 and a beta of 0.54.
Palvella Therapeutics Company Profile
(
Get Free ReportPalvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.
Recommended Stories
Before you consider Palvella Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Palvella Therapeutics wasn't on the list.
While Palvella Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
